Research Papers:
TTK is a favorable prognostic biomarker for triple-negative breast cancer survival
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2136 views | HTML 2796 views | ?
Abstract
Qianqian Xu1, Yali Xu1, Bo Pan1, Liangcai Wu2, Xinyu Ren3, Yidong Zhou1, Feng Mao1, Yan Lin1, Jinghong Guan1, Songjie Shen1, Xiaohui Zhang1, Changjun Wang1, Ying Zhong1, Liangrui Zhou3, Zhiyong Liang3, Haitao Zhao2, Qiang Sun1
1Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Correspondence to:
Qiang Sun, email: [email protected]
Haitao Zhao, email: [email protected]
Keywords: triple-negative breast cancer (TNBC), TTK, biomarker, prognostic indicator, survival analysis
Received: September 20, 2016 Accepted: October 19, 2016 Published: November 09, 2016
ABSTRACT
Purpose: Previous studies demonstrate that threonine and tyrosine kinase (TTK) is overexpressed in triple-negative breast cancer (TNBC), but there are conflicting results regarding its effect on TNBC survival. The purpose of this study was to assess the prognostic significance of TTK expression in primary TNBC.
Results: Of 169 consecutive cases eligible for this study, 164 included follow-up information. Cytoplasm and membrane TTK staining was observed in 99.4% of cases, while 5.9% displayed whole cell immunostaining. At a discriminating threshold of 55, elevated TTK expression was associated with prolonged disease free survival (DFS) (p < 0.001) and overall survival (OS) (p = 0.024) in primary TNBC and prolonged DFS in individual basal-like (p = 0.001) and non-basal-like (p = 0.001) TNBC subtypes. In addition, Cox regression analysis demonstrated that elevated TTK expression was an independent prognostic factor for DFS in TNBC (p < 0.001).
Methods: TTK expression of 169 samples was tested by immunohistochemistry (IHC). A receiver operating characteristic (ROC) curve was used to identify a cutpoint for TTK expression, which was analyzed for its association with patients’ clinicopathological factors and survival using Chi-square, log-rank, and Cox regression analyses.
Conclusions: TTK is a favorable prognostic biomarker associated with TNBC survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13245